Comparison · NCT01108445-sae
RAD001 vs Sunitinib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RAD001 vs Sunitinib: serious adverse events. Trial comparisons, record NCT01108445-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01108445-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.632 | 0.502 | 0.745 | wilson | |
| Risk in group 2 | 0.804 | 0.675 | 0.89 | wilson | |
| Risk difference, group 1 minus group 2 | -0.172 | -0.328 | -0.0011 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.786 | 0.618 | 0.999 | log | |
| Odds ratio, group 1 over group 2 | 0.418 | 0.174 | 1 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on RAD001 than on Sunitinib | 5.8 | 3.05 | 909 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RAD001 | Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.~Everolimus: Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle. | 36 | 57 | EG000 |
| Group 2 | Sunitinib | Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.~Sunitinib: 50 mg daily by mouth on days 1 through 28 of each 42 day cycle. | 41 | 51 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline to 40 months
Source ClinicalTrials.gov
Trial
- Title
- Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
- NCT number
- NCT01108445
- Phases
- PHASE2
- Conditions
- Advanced Non-clear Cell Renal Cell Carcinoma
- Interventions
- Everolimus, Sunitinib
- Lead sponsor
- Duke University
- Results first posted
- 2016-06-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01108445?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01108445-sae